Desk Notes | OSL OncoSil Medical (OSL) – Breaks Into the US Bynathan@prenzlergroup.com.au 18/08/202618/08/2026
Desk Notes | ENP Entropy (ENP) – 72 Patients, Nine Cohorts, Eight Disorders: Entropy Broadens the Platform Bynathan@prenzlergroup.com.au 04/08/202613/08/2026
CTS | Desk Notes CTS – Newly Listed Alzheimer’s Medical Device Targets US$18 billion Market, Debuts +132% Bynathan@prenzlergroup.com.au 28/07/202613/08/2026
Desk Notes | SNT SNT – 1st Cohort of AZALOX Trial Complete, Preliminary Data Expected Q4 CY26 Bynathan@prenzlergroup.com.au 21/07/202613/08/2026
Desk Notes | OSL OSL – Delivers on Milestones as Stock Re-Rates, Catalysts Still Ahead Bynathan@prenzlergroup.com.au 14/07/202613/08/2026
Desk Notes | ENP ENP – Entropy Reports Cohort 1 Topline Results in Treatment-Resistant Binge Eating Disorder Bynathan@prenzlergroup.com.au 10/07/202613/08/2026
Desk Notes | ILA ILA – Galidesivir Cleared for Compassionate Use in the Bundibugyo Ebola Outbreak Bynathan@prenzlergroup.com.au 07/07/202613/08/2026
Desk Notes | OSL OSL – Regulatory Progress Supports a Catalyst-Rich 2H CY2026 Bynathan@prenzlergroup.com.au 03/07/202613/08/2026
